286 related articles for article (PubMed ID: 33947209)
1. Predictors of Outcomes in Patients With Mild Ischemic Stroke Symptoms: MaRISS.
Romano JG; Gardener H; Campo-Bustillo I; Khan Y; Tai S; Riley N; Smith EE; Sacco RL; Khatri P; Alger HM; Mac Grory B; Gulati D; Sangha NS; Craig JM; Olds KE; Benesch CG; Kelly AG; Brehaut SS; Kansara AC; Schwamm LH;
Stroke; 2021 Jun; 52(6):1995-2004. PubMed ID: 33947209
[TBL] [Abstract][Full Text] [Related]
2. Frequency and Prognostic Significance of Clinical Fluctuations Before Hospital Arrival in Stroke.
Romano JG; Gardener H; Smith EE; Campo-Bustillo I; Khan Y; Tai S; Riley N; Sacco RL; Khatri P; Alger HM; Mac Grory B; Gulati D; Sangha NS; Olds KE; Benesch CG; Kelly AG; Brehaut SS; Kansara AC; Schwamm LH;
Stroke; 2022 Feb; 53(2):482-487. PubMed ID: 34645285
[TBL] [Abstract][Full Text] [Related]
3. Thrombolysis in Mild Stroke: A Comparative Analysis of the PRISMS and MaRISS Studies.
Asdaghi N; Romano JG; Gardener H; Campo-Bustillo I; Purdon B; Khan YM; Gulati D; Broderick JP; Schwamm LH; Smith EE; Saver JL; Sacco R; Khatri P
Stroke; 2021 Oct; 52(10):e586-e589. PubMed ID: 34496619
[TBL] [Abstract][Full Text] [Related]
4. Imaging negative stroke: diagnoses and outcomes in intravenous tissue plasminogen activator-treated patients.
Spokoyny I; Raman R; Ernstrom K; Meyer BC; Hemmen TM
J Stroke Cerebrovasc Dis; 2014; 23(5):1046-50. PubMed ID: 24103663
[TBL] [Abstract][Full Text] [Related]
5. Thrombolysis with alteplase 3-4.5 hours after acute ischaemic stroke: trial reanalysis adjusted for baseline imbalances.
Alper BS; Foster G; Thabane L; Rae-Grant A; Malone-Moses M; Manheimer E
BMJ Evid Based Med; 2020 Oct; 25(5):168-171. PubMed ID: 32430395
[TBL] [Abstract][Full Text] [Related]
6. Association of Recent Use of Non-Vitamin K Antagonist Oral Anticoagulants With Intracranial Hemorrhage Among Patients With Acute Ischemic Stroke Treated With Alteplase.
Kam W; Holmes DN; Hernandez AF; Saver JL; Fonarow GC; Smith EE; Bhatt DL; Schwamm LH; Reeves MJ; Matsouaka RA; Khan YM; Unverdorben M; Birmingham MC; Lyden PD; Asimos AW; Altschul D; Schoonover TL; Jumaa MA; Nomura JT; Suri MFK; Moore SA; Lafranchise EF; Olson D; Peterson ED; Xian Y
JAMA; 2022 Feb; 327(8):760-771. PubMed ID: 35143601
[TBL] [Abstract][Full Text] [Related]
7. Intravenous Thrombolysis With Alteplase at 0.6 mg/kg in Patients With Ischemic Stroke Taking Direct Oral Anticoagulants.
Okada T; Yoshimoto T; Wada S; Yoshimura S; Chiba T; Egashira S; Kimura S; Shiozawa M; Inoue M; Ihara M; Toyoda K; Takashima H; Koga M
J Am Heart Assoc; 2022 Oct; 11(19):e025809. PubMed ID: 36129032
[TBL] [Abstract][Full Text] [Related]
8. Effect of Alteplase vs Aspirin on Functional Outcome for Patients With Acute Ischemic Stroke and Minor Nondisabling Neurologic Deficits: The PRISMS Randomized Clinical Trial.
Khatri P; Kleindorfer DO; Devlin T; Sawyer RN; Starr M; Mejilla J; Broderick J; Chatterjee A; Jauch EC; Levine SR; Romano JG; Saver JL; Vagal A; Purdon B; Devenport J; Pavlov A; Yeatts SD;
JAMA; 2018 Jul; 320(2):156-166. PubMed ID: 29998337
[TBL] [Abstract][Full Text] [Related]
9. Low- Versus Standard-Dose Alteplase in Patients on Prior Antiplatelet Therapy: The ENCHANTED Trial (Enhanced Control of Hypertension and Thrombolysis Stroke Study).
Robinson TG; Wang X; Arima H; Bath PM; Billot L; Broderick JP; Demchuk AM; Donnan GA; Kim JS; Lavados PM; Lee TH; Lindley RI; Martins SCO; Olavarria VV; Pandian JD; Parsons MW; Pontes-Neto OM; Ricci S; Sato S; Sharma VK; Nguyen TH; Wang JG; Woodward M; Chalmers J; Anderson CS;
Stroke; 2017 Jul; 48(7):1877-1883. PubMed ID: 28619989
[TBL] [Abstract][Full Text] [Related]
10. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke.
Clark WM; Wissman S; Albers GW; Jhamandas JH; Madden KP; Hamilton S
JAMA; 1999 Dec; 282(21):2019-26. PubMed ID: 10591384
[TBL] [Abstract][Full Text] [Related]
11. Sex-Based Analysis of Workflow and Outcomes in Acute Ischemic Stroke Patients Treated With Alteplase Versus Tenecteplase.
Kim DJ; Singh N; Catanese L; Yu AYX; Demchuk AM; Lloret-Villas MI; Deschaintre Y; Coutts SB; Khosravani H; Appireddy R; Moreau F; Gubitz G; Tkach A; Dowlatshahi D; Medvedev G; Mandzia J; Pikula A; Shankar J; Williams H; Manosalva H; Siddiqui M; Zafar A; Imoukhuede O; Hunter G; Phillips S; Hill MD; Poppe AY; Ademola A; Shamy M; Bala F; Sajobi TT; Swartz RH; Almekhlafi MA; Menon BK; Field TS
Stroke; 2024 Feb; 55(2):288-295. PubMed ID: 38174568
[TBL] [Abstract][Full Text] [Related]
12. Tenecteplase-tissue-type plasminogen activator evaluation for minor ischemic stroke with proven occlusion.
Coutts SB; Dubuc V; Mandzia J; Kenney C; Demchuk AM; Smith EE; Subramaniam S; Goyal M; Patil S; Menon BK; Barber PA; Dowlatshahi D; Field T; Asdaghi N; Camden MC; Hill MD;
Stroke; 2015 Mar; 46(3):769-74. PubMed ID: 25677596
[TBL] [Abstract][Full Text] [Related]
13. Aphasia predicts unfavorable outcome in mild ischemic stroke patients and prompts thrombolytic treatment.
Nesi M; Lucente G; Nencini P; Fancellu L; Inzitari D
J Stroke Cerebrovasc Dis; 2014 Feb; 23(2):204-8. PubMed ID: 23352114
[TBL] [Abstract][Full Text] [Related]
14. Impact of Computed Tomography Perfusion Imaging on the Response to Tenecteplase in Ischemic Stroke: Analysis of 2 Randomized Controlled Trials.
Bivard A; Huang X; McElduff P; Levi CR; Campbell BC; Cheripelli BK; Kalladka D; Moreton FC; Ford I; Bladin CF; Davis SM; Donnan GA; Muir KW; Parsons MW
Circulation; 2017 Jan; 135(5):440-448. PubMed ID: 27965285
[TBL] [Abstract][Full Text] [Related]
15. Factors predicting outcome in stroke patients treated with 0.6 mg/kg alteplase: evidence from the Japan Alteplase Clinical Trial (J-ACT).
Mori E; Minematsu K; Nakagawara J; Yamaguchi T;
J Stroke Cerebrovasc Dis; 2011 Nov; 20(6):517-22. PubMed ID: 20719535
[TBL] [Abstract][Full Text] [Related]
16. Thrombolytic therapy for acute ischemic stroke after recent transient ischemic attack.
Alonso de Leciñana M; Fuentes B; Masjuan J; Simal P; Díaz-Otero F; Reig G; Díez-Tejedor E; Gil-Nuñez A; Vivancos J; Egido JA
Int J Stroke; 2012 Apr; 7(3):213-8. PubMed ID: 22098785
[TBL] [Abstract][Full Text] [Related]
17. Impact of an emergency medicine pharmacist on door to needle alteplase time and patient outcomes in acute ischemic stroke.
Barbour J; Hushen P; Newman GC; Vidal J
Am J Emerg Med; 2022 Jan; 51():358-362. PubMed ID: 34823191
[TBL] [Abstract][Full Text] [Related]
18. Early and continuous neurologic improvements after intravenous thrombolysis are strong predictors of favorable long-term outcomes in acute ischemic stroke.
Yeo LL; Paliwal P; Teoh HL; Seet RC; Chan BP; Wakerley B; Liang S; Rathakrishnan R; Chong VF; Ting EY; Sharma VK
J Stroke Cerebrovasc Dis; 2013 Nov; 22(8):e590-6. PubMed ID: 23954601
[TBL] [Abstract][Full Text] [Related]
19. Ethnicity and Other Determinants of Quality of Functional Outcome in Acute Ischemic Stroke: The ENCHANTED Trial.
Chen X; Wang X; Delcourt C; Li J; Arima H; Hackett ML; Robinson T; Lavados PM; Lindley RI; Chalmers J; Anderson CS;
Stroke; 2020 Feb; 51(2):588-593. PubMed ID: 31822251
[TBL] [Abstract][Full Text] [Related]
20. Tenecteplase Versus Alteplase Between 3 and 4.5 Hours in Low National Institutes of Health Stroke Scale.
Rønning OM; Logallo N; Thommessen B; Tobro H; Novotny V; Kvistad CE; Aamodt AH; Næss H; Waje-Andreassen U; Thomassen L
Stroke; 2019 Feb; 50(2):498-500. PubMed ID: 30602354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
